Four forces changing the 2027 self-funded renewal
Health In Tech · October 6, 2026
Renewal season can compress a year of risk into a premium comparison. Yet two proposals with similar rates may leave an employer with very different exposure once claimant-specific terms, specialty treatment provisions and the time allowed to pay claims are taken into account. For 2027, brokers can add value by showing how each proposal would perform under a difficult claim, then helping the sponsor choose a level of risk it can carry.
Corporate employers surveyed by the International Foundation of Employee Benefit Plans project a median 10% increase in medical plan costs for 2027, with catastrophic claims and costly prescription drugs among the leading concerns. That forecast gives brokers a reason to sharpen renewal preparation, while each group’s claims history, reserves and contracts remain the basis for its decisions.
1. Stop-loss: compare the risk retained, not only the rate
Segal’s 2026 dataset of 225 health plans found an average stop-loss premium increase of 12.7% among plans that maintained similar specific stop-loss benefit levels, up from 9.7% the prior year. Segal also observed continued growth in seven-figure claimants in its claims data. As that exposure rises, the terms governing reimbursement become more consequential to a sponsor’s budget and cash flow.
A laser, for example, excludes an individual claimant or assigns that person a higher specific deductible, leaving the employer responsible for more of the claim. Before recommending a lower-premium option, put the proposals on a comparable footing: show the specific and aggregate deductibles, any lasers, pharmacy and specialty treatment terms, claims run-out and renewal protections in one view. Then model what the group would fund, and when it could expect reimbursement, under a plausible high-cost claim. For a sponsor seeking more predictability, ask whether a provision barring new lasers alongside a renewal rate cap is available and evaluate its cost against the protection it provides.
2. High-cost care: plan differently for ongoing spend and a single large claim
The stop-loss contract establishes where a large claim lands; claims and pharmacy data help reveal which exposures need attention before renewal. In the International Foundation’s 2026 GLP-1 survey, drugs used for weight loss represented an average of 11.4% of total annual claims for corporate respondents in 2025. That is an ongoing spending question shaped by coverage criteria, utilization and net drug costs. Cell and gene therapies present a different challenge: EBRI’s analysis of employer health plans found that their use remains rare, while spending is concentrated among a small number of high-cost claimants. Employers also report rising oncology costs.
Those differences call for distinct reviews. For GLP-1s, ask the PBM and administrator to show utilization by covered indication, net spend after rebates and the effect of current coverage criteria. For oncology, examine access to navigation, second opinions and appropriate treatment settings alongside cost and outcomes. For cell and gene therapies, confirm how the stop-loss policy treats the claims and whether an exclusion or separate arrangement changes the employer’s exposure. Bringing the PBM, administrator and stop-loss underwriter into that discussion early helps ensure the benefit design and risk coverage reflect the same assumptions.
3. AI: measure what improves between submission and binding
The data work behind a renewal is changing, but adoption figures alone say little about the broker’s experience. In a NAIC survey of 93 health insurers, 84% reported using AI or machine learning in some capacity across product lines that included group major medical. Reported uses included prior authorization, fraud detection, and online sales and quoting.
A better starting point is to map the current submission process. Where are census and plan details entered more than once? How long does a case wait for missing information, and how often do terms change between an initial quote and a firm offer? Automation may help with repeatable intake and document checks, while people remain responsible for resolving exceptions and confirming the final terms. Ask technology and carrier partners how they verify inputs, protect sensitive information and document decisions. The NAIC’s AI model bulletin gives insurers a framework for governance and accuracy, making those questions part of sound partner due diligence.
4. PBM transparency: prepare the contract before the deadline
The same need for clear information extends beyond the quote to the arrangements that determine what a plan pays. The Consolidated Appropriations Act of 2026 establishes future PBM reporting and rebate pass-through requirements. The relevant provisions generally apply to plan years beginning 30 months after the law’s February 3, 2026 enactment and to covered contracts entered into, renewed or extended after the effective date. Separately, the Department of Labor has proposed more detailed compensation disclosures for PBMs and affiliated brokerage and consulting providers serving self-insured ERISA plans.
For next year, the useful step is to establish what the sponsor can verify under its current agreement. Request the PBM contract and amendments, trace how rebates, fees and affiliate payments are defined, and identify the reporting and audit rights available to the plan. Benefits counsel can then assess which terms deserve attention before the next PBM sourcing decision or contract renewal. That preparation gives the sponsor a clearer view of the arrangement today and a stronger position when the new requirements take effect.
What connects the four
These trends make it more valuable for brokers to show clients what sits behind a quote: where risk is transferred, which costs may recur and how options compare. That level of guidance takes time. By connecting quoting and marketplace access in one workflow, our technology helps brokers spend less time coordinating submissions and more time advising clients and pursuing new business.
If you’re planning for 2027, connect with our team for a consultation. We’ll look at your book of business, discuss where quoting and placement slow you down, and explore opportunities to create more room for growth.
